Can a Triple-Drug combo outsmart stubborn stomach cancer?
NCT ID NCT07025889
First seen Aug 18, 2026 · Last updated Aug 18, 2026
Summary
This trial is testing whether combining an experimental drug called IBI343 with an immunotherapy (sintilimab) and standard chemotherapy can help people with a specific type of advanced stomach or gastroesophageal junction cancer. The study focuses on patients whose tumors have a protein called CLDN18.2 and lack HER2, and who have not yet received systemic treatment. The goal is to see if this combination can shrink tumors and improve how long patients live, while monitoring safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI343 (an experimental antibody-drug conjugate) combined with sintilimab (an immunotherapy) and chemotherapy (oxaliplatin and S-1)
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for people with a specific type of advanced gastric cancer, potentially improving tumor shrinkage and survival.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not hold up in larger studies. The combination may also cause significant side effects, including immune-related reactions and chemotherapy toxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo beat single painkiller after stomach surgery?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Can surgery for stomach or esophageal cancer cloud the mind?